|
    BCEL U.S.: Nasdaq

    Atreca Inc. Cl A

    BCELUS
    Open
    Back To Top
    Last Updated: May 17, 2021 12:25 p.m. EDT Real time quote

    $ 9.50

    -0.08 -0.84%
    Previous Close
    $9.58
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 96.89K 65 Day Avg: 233.93K
    41% vs Avg
    9.31 Day Range 9.91
    8.87 52 Week Range 25.03

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    BCEL Overview

    Performance

    5 Day
    • -2.16%
    1 Month
    • -17.03%
    3 Month
    • -50.24%
    YTD
    • -41.18%
    1 Year
    • -49.06%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 10 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Atreca started at outperform with $27 stock price target at Wedbush

    Read full story

    Stanford University Now Owns Stakes in Uber and Pinterest Stock

    Atreca started at buy with $28 stock price target at Stifel Nicolaus

    Atreca started at outperform with $35 stock price target at Evercore ISI

    Atreca looks to raise up to $132.3 million in IPO

    • Other News
    • Press Releases

    Atreca (BCEL) Receives a Buy from Canaccord Genuity

    on SmarterAnalyst

    Atreca (BCEL) Gets a Buy Rating from H.C. Wainwright

    on SmarterAnalyst

    Atreca (BCEL) Receives a Buy from Brookline Capital Markets

    on SmarterAnalyst

    Atreca (BCEL) Gets a Buy Rating from Canaccord Genuity

    on SmarterAnalyst

    Atreca (BCEL) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    What's in Store for Zomedica (ZOM)This Earnings Season?

    on Zacks.com

    What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?

    on Zacks.com

    Atreca (BCEL) Initiated with a Buy at Jefferies

    on SmarterAnalyst

    Atreca (BCEL) Receives a Buy from H.C. Wainwright

    on SmarterAnalyst

    Atreca (BCEL) Gets a Buy Rating from Canaccord Genuity

    on SmarterAnalyst

    What Makes Atreca, Inc. (BCEL) a New Buy Stock

    on Zacks.com

    Jeffries Rates IGM Biosciences a Buy in Health Care Sector

    on GuruFocus.com

    Atreca, Inc. (BCEL) Upgraded to Buy: Here's Why

    on Zacks.com

    All You Need to Know About Atreca, Inc. (BCEL) Rating Upgrade to Buy

    on Zacks.com

    Atreca Inc. Cl A

    Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in South San Francisco, CA.